Research & Development

The recent resignation of Peter Marks as the head of the FDA's Center for Biologics Evaluation and Research (CBER) marks a significant moment for the cell and gene therapy industry. His departure has sparked widespread discussion about the future direction of the regulatory landscape and its

Bayesian methods are revolutionizing the landscape of pediatric clinical trial design by offering flexibility, precision, and ethical considerations that are crucial when dealing with vulnerable populations. These approaches are particularly suited to the unique challenges of pediatric trials,

Clinical trials have long been a cornerstone of medical research, essential for the development and approval of new drugs and treatments. However, they are often plagued by high costs, time constraints, and the complexities associated with patient recruitment. In recent years, the transformative

Schrödinger, a well-established player in the computational chemistry and drug discovery space, has recently made headlines by embracing artificial intelligence (AI). The company’s CEO, Ramy Farid, officially announced this strategic pivot during the presentation of the company's year-end re

The pharmaceutical landscape is rapidly evolving, and at the forefront of these advancements is Merck & Co.'s groundbreaking licensing agreement with Jiangsu Hengrui Pharmaceuticals, focusing on the innovative Lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. This monumental $2 billion deal puts

Retinitis pigmentosa, an inherited retinal disease, is characterized by progressive vision loss over time, ultimately leading to severe visual impairment. The disease affects the retinal photoreceptor cells, where the degeneration results in the gradual loss of night vision, peripheral vision, and